相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma
P. Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis
Ruiying Zhao et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
Xibin Zhuang et al.
CANCER MEDICINE (2019)
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Recent progress in systemic treatment for lung cancer
Jeffrey W. Clark et al.
CURRENT OPINION IN PULMONARY MEDICINE (2018)
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
Akira Yokoyama et al.
INTERNAL MEDICINE (2018)
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer
Petros Christopoulos et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Igor Letovanec et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
Chun-wei Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib
Wen-Xian Wang et al.
JOURNAL OF THORACIC DISEASE (2018)
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
A. Kron et al.
ANNALS OF ONCOLOGY (2018)
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results
J. Kevin Hicks et al.
LUNG CANCER (2017)
Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology
Adriane F. Evangelista et al.
BMC PULMONARY MEDICINE (2017)
Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting
Pasquale Pisapia et al.
JOURNAL OF THORACIC DISEASE (2017)
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
C. Mayo-de-las-Casas et al.
ANNALS OF ONCOLOGY (2017)
Structural determinants of TRIM protein function
Diego Esposito et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2017)
Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients
Song Xu et al.
CANCER LETTERS (2016)
EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect
Nora Sahnane et al.
CLINICAL LUNG CANCER (2016)
Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base
Brian N. Arnold et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Scientific Advances in Lung Cancer 2015
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer
Huan Qiao et al.
CANCER DISCOVERY (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
Chia-Hung Hsu et al.
ONCOTARGET (2016)
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
Sanja Dacic et al.
ONCOTARGET (2016)
Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases
Yongfeng Yu et al.
SPRINGERPLUS (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review
Ning Zhao et al.
CLINICAL LUNG CANCER (2015)
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
Weijing Cai et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor
J. K. Won et al.
ANNALS OF ONCOLOGY (2015)
Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
Jin-Ji Yang et al.
CLINICAL CANCER RESEARCH (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
HIP1-ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
Douglas D. Fang et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis
Matthew S. Lara et al.
LUNG CANCER (2014)
Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells
Licia Baldi et al.
LUNG CANCER (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma
Hyo Jae Kang et al.
RESPIRATORY MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Radiotherapy for Stage III Non–Small-Cell Lung Carcinoma in the Elderly (Age ≥ 70 years)
Paul D. Aridgides et al.
Clinical Lung Cancer (2013)
The Switch-associated Protein 70 (SWAP-70) Bundles Actin Filaments and Contributes to the Regulation of F-actin Dynamics
Carlos Andres Chacon-Martinez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer
Ying Li et al.
PLOS ONE (2013)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
June Koo Lee et al.
LUNG CANCER (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Florent Mouliere et al.
PLOS ONE (2011)
The Golgin Coiled-Coil Proteins of the Golgi Apparatus
Sean Munro
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
Emerging roles for WNK kinases in cancer
Sonia Moniz et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ALK Gene Rearrangements A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
Young Lim Choi et al.
CANCER RESEARCH (2008)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
分享论文
